{
  "name" : "twin.sci-hub.se_6199_aa367495f003597d4825b1dbecbe3c48_10.2337@db16-0473.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Associations of Steroid Sex Hormones and Sex Hormone-Binding Globulin with the Risk of Type 2 Diabetes in Women: a Population-Based Cohort Study and Meta-Analysis",
    "authors" : [ "Taulant Muka", "Jana Nano", "Loes Jaspers", "Cindy Meun", "Wichor M. Bramer", "Albert Hofman", "Abbas Dehghan", "Maryam Kavousi", "Joop S.E. Laven", "Oscar H. Franco" ],
    "emails" : [ "t.muka@erasmusmc.nl" ],
    "sections" : [ {
      "heading" : null,
      "text" : "It remains unclear whether endogenous sex hormones (ESH) are associated with risk of type 2 diabetes (T2D) in women. Data of 3117 postmenopausal women participants of the Rotterdam Study (RS) were analysed to examine whether ESH and sex hormone-binding globulin (SHBG) were associated with the risk of incident T2D. Additionally, we performed a systematic review and meta-analysis of studies assessing the prospective association of ESH and SHBG with T2D in women. During a median follow-up of 11.1 years, we identified 384 incident cases of T2D in the RS. No association was observed between total (TT) or bioavailable testosterone (BT) with T2D. SHBG was inversely associated with the risk of T2D whereas total estradiol (TE) was associated with increased risk of T2D. Similarly, in the meta-analysis of 13 population-based prospective studies involving more than 1912 incident T2D cases, low levels of SHBG and high levels of TE were associated with increased risk of T2D, while no associations were found for other hormones. The association of SHBG with T2D did not change by menopause status, while the associations of ESH and T2D were based only in postmenopausal women. SHBG and TE are independent risk factors for the development of T2D in women.\n3"
    }, {
      "heading" : "INTRODUCTION",
      "text" : "Menopause is an important transition in women’s life, not only for marking the end of reproductive life, but also for being accompanied by an increased risk of cardiovascular disease and type 2 diabetes (T2D) (1; 2). Changes in hormonal patterns in menopause, including the decline in endogenous estradiol levels and the relative androgen excess, contribute to an increase in visceral adiposity that is associated with glycemic traits, and therefore may influence the risk of T2D (3; 4). Furthermore, polycystic ovary syndrome, a common disorder among women characterised by hyperandrogenism, has been identified as a significant non-modifiable risk factor associated with T2D (5).\nWhile the relation between sex-hormone binding globulin (SHBG) and T2D has long been recognized (6; 7), literature on the associations of steroid sex hormones such as endogenous estradiol (E) and testosterone (T) with T2D is scarce. SHBG, T and E have been associated with glucose metabolism and development of insulin resistance (6-9). Few epidemiological studies investigating the relation between sex hormones and T2D have yielded conflicting results (10- 12). These studies were limited by their cross-sectional design, selected samples, or insufficiently adjustment for diabetes risk factors. To date, no large prospective cohort study has examined the association of T2D with SHBG, T and E in healthy postmenopausal women. Thus, we aimed to investigate the association between SHBG, sex hormones and T2D in postmenopausal women. Furthermore, to clarify the contradictory results, we systematically reviewed and meta-analysed studies evaluating the association between SHBG, sex hormones and T2D in women.\nSUBJECTS AND METHOD\n4"
    }, {
      "heading" : "The Rotterdam Study",
      "text" : "The Rotterdam Study is a prospective cohort study which started since 1990 in the Ommoord district, in the city of Rotterdam, The Netherlands. Details regarding the design, objectives, and methods of the Rotterdam Study have been described in detail elsewhere(13). In brief, in 1990 all inhabitants of a well-defined district of Rotterdam were invited, of whom 7,983 agreed (78.1%). In 2000, an additional 3011 participants were enrolled (RS-II), consisting of all persons living in the study district who had become 55 years of age. Follow up examinations were performed periodically, approximately every 3-5 years(13). There were no eligibility criteria to enter the Rotterdam Study cohorts except the minimum age and residential area based on ZIP codes. The Rotterdam Study has been approved by the medical ethics committee according to the Population Screening Act: Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the Netherlands. All participants in the present analysis provided written informed consent to participate and to obtain information from their treating physicians."
    }, {
      "heading" : "Ascertainment of type 2 diabetes",
      "text" : "The participants were followed from the date of baseline center visit onwards. At baseline and during follow-up, cases of T2D were ascertained through active follow-up using general practitioners’ records, glucose hospital discharge letters and glucose measurements from Rotterdam Study visits which take place approximately every 4 years (14). T2D was defined\naccording to recent WHO guidelines, as a fasting blood glucose ≥ 7.0 mmol/L, a non-fasting\nblood glucose ≥ 11.1 mmol/L (when fasting samples were absent), or the use of blood glucose\nlowering medication (15). Information regarding the use of blood glucose lowering medication was derived from both structured home interviews and linkage to pharmacy records (14). At baseline, more than 95% of the Rotterdam Study population was covered by the pharmacies in\n5\nthe study area. All potential events of T2D were independently adjudicated by two study physicians. In case of disagreement, consensus was sought with an endocrinologist. Follow-up data was complete until January 1 st 2012."
    }, {
      "heading" : "Sex steroid measurements",
      "text" : "All blood samples were drawn in the morning (≤ 11:00 am) and were fasting. Total estradiol (TE) levels were measured with a radioimmunoassay and SHBG with the Immulite platform (Diagnostics Products Corporation Breda, the Netherlands). The minimum detection limit for estradiol was 18.35 pmol/liter. Undetectable estradiol was scored as 18.35. Serum levels of total testosterone (TT) were measured with liquid chromatography-tandem mass spectrometry (LC-MS/MS). The corresponding interassay coefficients of variations for TE, SHBG and TT are <7%, <5%, and <5%. Free androgen index (FAI), calculated as (T/SHBG)*100 is used as a surrogate measure of bioavailable testosterone (BT) (16)."
    }, {
      "heading" : "Population of analysis",
      "text" : "The present study used data from the third visit of the first cohort (RSI-3) and the baseline examinations of the second (RSII-1) cohort. Overall, there were 3,683 postmenopausal women eligible for blood measurements. Among them, 122 women did not come for a blood measurement at the research center and 32 did not have T2D follow-up data and were , excluded from the analysis. Furthermore, 412 women with prevalent T2D were excluded, leaving 3,117 for our final analysis.\nPotential confounding variables are described in detail in S1 Appendix.\n6"
    }, {
      "heading" : "Statistical analysis",
      "text" : "Person years of follow-up were calculated from study entrance (March 1997- December 1999 for RSI-3, February 2000-December 2001 for RSII-1) to the date of diagnosis of T2D, death or the censor date (date of last contact of the living), whichever occurred first. Follow-up was until January 1 st 2012. Cox proportional hazard modelling was used to evaluate whether SHBG, TT, TE and BT were associated with T2D. Relative Risks (RR) and 95% confidence intervals (95% CIs) were reported. All sex hormones variables were assessed in separate models, continuously and in tertiles. For estradiol, first tertile included all women with levels of estradiol lower than the detection limit (n=992). To study the relations across increasing tertiles, trend tests were computed by entering the categorical variables as continuous variables in multivariable Cox’s proportional hazard models. To achieve approximately normal distribution, skewed variables (SHBG, TT, BT, plasma triglyceride, low density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), thyroid-stimulating hormone (TSH) and insulin) were natural log transformed. In the base model (Model 1), we adjusted for age, cohort (1 and 2), fasting status (fasting sample vs. non-fasting sample). To examine whether the relations of sex hormones and SHBG with risk of T2D were independently of established risk factors for T2D, model 2 included terms of model 1, body mass index (BMI) (continuous), glucose (continuous) and insulin (continuous). BMI and waist circumference were highly correlated (Pearson’s correlation coefficient = 0.81, P<0.001), so only BMI was used as a measure of adiposity, consistent with previous studies (10; 17). Model 3 included all covariates in model 2 and further potential intermediate factors including: metabolic risk factors (total cholesterol, systolic blood pressure (continuous), indication for hypertension (yes vs. no) and use of lipid-lowering medications (yes vs. no)), lifestyle factors (alcohol intake (continuous) and smoking status (current vs. former/never)), prevalent coronary\n7\nheart disease (yes vs. no), age of menopause, hormone replacement therapy (yes vs. no), CRP (continues) and sex hormones for each other. Effect modifications of sex hormones by BMI and years since menopause were tested in the final multivariable model in addition to performing stratified analysis. We also performed a series of sensitivity analyses. Since waist circumference is a better measure of visceral adiposity, an important risk factor for diabetes and of sex hormone levels after menopause, we performed the analysis substituting it with BMI. To account for the specific effects of lipid particles on diabetes, we substituted total cholesterol with HDL-C, triglycerides and LDL-C. TSH, physical activity, number of pregnancies and type of menopause ((non-natural vs. natural) are associated with sex hormone levels and/or risk of T2D, therefore, the models were further adjusted for these factors. To explore potential reverse causation, we reran the analysis by excluding the first three years of follow up. Multiple imputation procedure was used (N= 5 imputations) to adjust for potential bias associated with missing data. Rubin’s method was used for the pooled regression coefficients (β) and 95% Confidence Intervals (18). A p-value of less than 0.05 was considered as statistically significant. All analyses were done using SPSS statistical software (SPSS, version 21.0; SPSS Inc, Chicago, Illinois)."
    }, {
      "heading" : "Systematic Review and Meta-Analysis",
      "text" : "Data sources and search strategy The review was conducted using a predefined protocol and in accordance with the PRISMA(19) and MOOSE(20) guidelines (S2 and S3 Appendix). Medline, Embase.com, Web of Science, the Cochrane Llibrary, PubMed and Google Scholar were searched from inception until November 2 nd 2015 (date last searched) with assistance of an experience biomedical information specialist. The computer-based searches combined terms related to the exposure (eg, sex hormone binding\n8\nglobulin, testosterone, estradiol) with outcomes (eg, type 2 diabetes), without any language restriction. Details on the search strategy are provided in S4 Appendix.\nStudy selection and eligibility criteria Studies were included if they (i) were observational cohort, case-cohort studies, or prospective nested case control studies; (ii) had reported on at least one of the sex hormones as exposures: SHBG, TT, BT, TE and bioavailable estradiol (BE); and (iii) had assessed associations with risk of T2D in women (pre and postmenopausal). Two independent reviewers screened the titles and abstracts of all initially identified studies according to the selection criteria. Full texts were retrieved from studies that satisfied all selection criteria.\nData extraction, quality assessment and data synthesis and analysis are described in detail in S5"
    }, {
      "heading" : "Appendix",
      "text" : ""
    }, {
      "heading" : "RESULTS",
      "text" : "Table 1 summarizes the baseline characteristics of the participants included in the analysis. Of the 3117 postmenopausal women without diabetes at baseline, 384 women developed diabetes over a median follow-up of 11.1 years."
    }, {
      "heading" : "Sex-hormones and the risk of developing T2D",
      "text" : "In models adjusted for age, cohort effect and fasting status, lower SHBG levels (3 rd tertile vs.1 st tertile: RR=0.33, 95% CI=0.25 -0.43, p-trend<0.001) and higher levels of BT (3 rd tertile vs.1 st tertile: RR=2.01, 95% CI=1.55-2.60, p-trend<0.001) and TE (3 rd tertile vs.1 st tertile: RR=2.02, 95% CI=1.50 -2.70, p-trend<0.001) were associated with an increased risk of T2D (Table 2).\n9\nFurther adjustments for BMI, insulin and glucose attenuated but did not abolish the association between SHBG (3 rd tertile vs.1 st tertile: RR=0.56, 95% CI=0.41 -0.77, p-trend<0.001) or TE and incident T2D (3 rd tertile vs.1 st tertile: RR=1.39, 95% CI=1.004 -1.93, p-trend=0.07). On the other hand, adjustment for obesity and glycemic traits weakened the associations of BT with T2D such that they were not longer statistically significant (Table 2). Controlling for metabolic risk factors, lifestyle factors, inflammatory markers and prevalent coronary heart disease did not materially affect these associations (Table 2). No association was found between TT and incident T2D in any of the models (Table 2).\nBecause associations of continues hormone variables with T2D in the Model 1 appeared linear, RRs stratified and sensitivity analyses were expressed per unit log or unit increase in hormone biomarkers. In the sensitivity analyses, substituting BMI with waist circumference as a measure of adiposity, substituting total cholesterol for other blood lipids, adjusting further for serum TSH, physical activity, number of pregnancies of at least 6 months or menopause type, and excluding the first three years of follow up did not affect any of the associations (S1 Table). Also, in the stratification analysis, no significant interactions were found for SHBG and TE with BMI or years since menopause (S1 Table). Significant interaction terms were found for TT (pinteraction = 0.019) and FAI (p-interaction = 0.03) with years since menopause. However, no association was found between these hormones and T2D after stratification for time since menopause (S1 Table). Also, no effect modification by BMI was found for TT and BT (S1 Table)."
    }, {
      "heading" : "Systematic Review and Meta-Analysis",
      "text" : "Literature Search, Characteristics and Quality of Eligible Studies\n10\nInitial search identified 3209 potentially relevant citations. After screening and detailed assessment, 15 articles based on 12 unique studies were included (S1 Figure and S5 Appendix). Therefore, we meta-analysed estimates from 13 studies (including the current study) involving a total of 14,902 pre- and postmenopausal women with 1912 incident T2D cases reporting on the association between sex hormones and T2D risk. Detailed characteristics of these studies and quality assessment have been summarized in S2 Table. All studies were medium to high quality except one."
    }, {
      "heading" : "Sex hormones and T2D in Pooled Analysis",
      "text" : "The meta-analyses for BT, TE and BE are based only on studies examining postmenopausal women; the meta-analysis for TT is based on 4 studies including postmenopausal women and 1 study including pre and postmenopausal women, whereas the findings for SHBG derive from studies including premenopausal women (n=2), postmenopausal women (n=4) and combined (n=3). The pooled RR for T2D adjusted for several metabolic risk factors comparing 3 rd tertile vs. 1 st tertile of SHBG, TT, BT, TE and BE were 0.44 (95%CI: 0.30-0.66, I 2 =77,9%, p<0.001), 1.32 (95%CI: 0.79-2.21, I 2 =53.8%, p=0.07), 1.75 (95%CI: 0.92-3.33, I 2 =80.7%, p=0.001), 1.99 (95%CI: 1.21-3.27, I 2 =55.1%, p=0.06) and 3.58 (95%CI: 0.86-14.84, I 2 =81.0%, p=0.02) (Figure 1-3). There was evidence of between-study heterogeneity for all these analyses with possible exception of the meta-analysis on the association between TE and the risk of T2D (Figure 1-3). For SHBG, heterogeneity was not explained by any of the study-level characteristics assessed such as menopause status, location and number of participants (S4 Table). For TT, the level of heterogeneity was largely explained by location (S4 Table). Five studies were not possible to include in the meta-analyses. Soriguer found that, in pre- and postmenopausal women, per one unit log increase in SHBG, TT and BT, the corresponding RRs were 0.23 (0.1 to 0.53), 1.04\n11\n(0.59 to 1.83) and 1.12 (0.59 to 2.13) respectively. Boyd-Waschinko at al. reported a 5-fold increase in T2D incidence in the lowest quintile of SHBG. Similarly, Lindstedt et al. found that among patients in the low SHBG terile, 18% converted to T2D as compared with 5% in mid SHBG tertile and 2.5% in high SHBG tertile. Okubo et al reported lower levels of SHBG in T2D converters (59.7 ± 8.4 nmol/l) than non-converters (69.5 ± 2.5 nmol/l) during 3 years of followup but that was not significant different after adjusting for age, body mass index and waist to hip ratio(21). Sex steroids and SHBG were not associated with diabetes outcomes in pre and postmenopausal women in the study of Mather et al (22)."
    }, {
      "heading" : "Publication bias",
      "text" : "The appearance of funnel plots was asymmetrical for the analysis on SHBG and T2D, and Egger's test results were significant (P = 0.014) (S2 Figure). This suggested that publication bias may be present. After exclusion of the four studies that included 50 or fewer T2D cases findings were not statistically significant (Egger’s test, P=0.93, data not shown). No evidence of publication bias was observed for the analysis of TT or TE and T2D (S2 Figure)."
    }, {
      "heading" : "DISCUSSION",
      "text" : "In this large population based study of postmenopausal women free of T2D at baseline, we showed that that lower levels of SHBG and higher levels of TE were associated with the risk of T2D, independently of established risk factors for T2D, including body mass index, glucose and insulin. In contrast, the association between testosterone and the risk of T2D was explained by body mass index, glucose and insulin. Pooled results from the systematic meta-analysis of 13 studies reinforce the validity and generalizability of our findings, suggesting that SHBG and TE are robust risk markers of T2D in women.\n12\nUnlike the previous meta-analysis by Ding EL et al, which was based mainly on studies with\ncross-sectional design and examined only mean differences between T2D cases and non T2D controls, our current pooled analysis is based on findings from 13 prospective studies (only two studies were included in the previous review were eligible), including 10873 participants with 1623 T2D cases. Therefore, our meta-analysis provides a more detailed assessment of the nature and magnitude of the association between sex hormones and T2D in women.\nSHBG levels have been associated with metabolic syndrome, glucose and insulin levels, established risk factors for T2D(7; 8; 23). Also, women with PCOS, a condition of anovulation and hyperandrogenism, are at increased risk of T2D, and levels of SHBG are decreased in these women (24). The complex biological mechanisms that explain the association between circulating SHBG levels and the risk for T2D are not fully understood. Classically, the primary function of SHBG was thought to be the binding of circulating hormones in order to regulate free sex hormone bioavailability to target tissues. Therefore, it has been hypothesized that the relation between SHBG and T2D may results from indirect influence of alterations in SHBG on sex hormone bioavailability. However, in our study, the association between SHBG and T2D risk remains significant after adjustment for TT, BE and TE, implicating SHBG levels as a risk factor for T2D independent of serum androgen levels. Additional evidence in support of an independent effect of SHBG on T2D comes from recent studies that have found several polymorphisms in the SHBG to associate with insulin resistance and T2D, suggesting that altered SHBG physiology may be a primarily defect in the pathogenesis of disease(25-28). Furthermore, a growing body of evidence show that SHBG may directly mediate cell-surface signalling, cellular delivery and biologic action of sex hormones via activation of a specific plasma receptor(29-31). At the target tissue level, the fraction of SHBG that is not bound to sex steroid has the ability to bind plasma\n13\nmembrane high-affinity receptors (RSHBG)(29). Sex steroids of variable biologic potency can activate the anchored SHBG- RSHBG complex and the activated complex can have either an agonist or antagonist effect. For example, SHBG- RSHBG complex can have direct cellular antagonistic properties against estrogen; SHBG may interact with cellular estrogen receptors which can trigger a biologic antiestrogenic response(29). Specific downstream effects of the SHBG-receptor complex merit further investigation since may help to clarify the underlying mechanisms linking SHBG to T2D.\nOur result for a positive relation between estradiol and T2D are in contrast with the results from previous large randomized control trials of oral estrogen therapy, which showed a lower risk of T2D among postmenopausal women assigned to estrogen treatment(32-34). However, due to the observational design, our study does not provide causality. Mendelian Randomization experiments are warranted to investigate the potential causal implications of estradiol on T2D. Exogenous estrogen may have different physiological effects depending on type, route, duration and dose of estrogen therapy(35-38). For example, opposing effects of oral estrogen on fasting glucose vs glucose tolerance have been reported(35; 36). Also, in a randomized trial of postmenopausal women, oral estrogen elevated C-reactive protein levels up to 12 months of treatment but not transdermal estradoil (38). Moreover, a bimodal relationship of estrogen dose may exist. In a clinical trial of postmenopausal women, lower dose of estrogen therapy increased insulin sensitivity whereas higher dose had the opposite effect(39).\nIn postmenopausal women, endogenous estradiol may be associated with diabetes risk through its relation to glucose, insulin, obesity and inflammation. Indeed, previous cross-sectional studies have linked both BE and TE with higher glucose and insulin resistance levels in postmenopausal women, independently of obesity (9; 40; 41). Also, while animal studies suggest estradiol\n14\nregulate body composition, may studies in postmenopausal women have failed to show a consistent beneficial role of estradiol in weight loss and in the distribution of body fat(42). However, in our study, the association between TE and T2D, although attenuated, remained significant after adjustment for plasma levels of glucose and insulin, BMI and CRP, suggesting that estradiol may play a direct role in the pathophysiology of T2D in postmenopausal women. Furthermore, additional adjustment for TT did not affect this association, suggesting that estradiol may be more than just a marker of increased aromatase conversion. Explicit mechanisms of estrogen in relation to T2D require further study.\nOur study showed no association between TT and the risk of T2D whereas a suggestive positive association was observed between BT and T2D. The lack of association between FT and the risk of T2D in our study might be due to lack of a direct measure of BT in the blood which could have biased our results toward the null. These findings are in line with previous studies reporting higher levels of insulin resistance with increasing levels of BT in postmenopausal women, while no association has been observed between TT and insulin resistance(14; 41). Similarly, BT has been related to increased odds of having impaired fasting glucose(14).\nStrengths of our study include its prospective design; the long follow-up and adequate adjustments for a broad range of possible confounders. We also performed several sensitivity analyses such as excluding the first three years of follow up to avoid potential bias of undiagnosed disease at baseline. Furthermore, our study included in addition to analysis of primary data also a systematic review of all available published prospective cohorts, which is the first-ever quantitative synthesis of these associations thus far in women. Also, most of the studied included in our meta-analysis adjusted for potential confounding. However, there are several limitations that need to be taken into account. First, we did not have measures of\n15\nbioavailable estradiol in the Rotterdam Study, which could have strengthened our results. Also, TE was measured using an immunoassay with a detection limit of 18.35 pmol/L, which is considered suboptimal particularly in postmenopausal women. However, the observed effect remained the same while analysing TE continuously and categorically. Second, free T levels were not measured directly in the blood and therefore have to be interpreted with caution. Nevertheless, free T levels in this study were derived from the ratio of T to SHBG, which is considered a precise proxy for bioavailable T(43). Third, we observed a moderate to high level of heterogeneity across the included studies. Different assays (S3 Table) used to assess the levels of sex hormones and SHBG contributed to the observed heterogeneity. However, since the number of available studies included in each meta-analysis was generally small, it precluded our ability to conduct subgroup analyses involving various study-level characteristics (such as age). Fourth, there was evidence of publication bias for the association between SHBG and the risk of T2D, so it is possible that our results constitute an overestimation of the performance of the test. However, when we excluded small studies differences were not statistically significant and therefore, the effect of publication bias may be only minor. Fifth, except for SHBG, the other findings come from studies conducted mainly in postmenopausal women, and thus, these results cannot be extended to pre or perimenopause women. Finally, contrary to the results of randomeffect models, the fixed-effect models showed a significant association of both BE and BT with the risk of T2D. The differences in random vs. fixed effects models might be explained by the substantial heterogeneity observed between-studies (for example, in the association of BT), which could be better captured under the random effects model (44). For BE, the small-size of the studies might undermine the precision of the estimate under a fixed effects model. However, in light of these observations, the overall results of this study should be interpreted with caution.\n16\nIn conclusion, lower levels of SHBG and higher levels of TE are independently associated with risk of T2D risk in postmenopausal women. Further studies are needed to establish hormones thresholds at which diabetes risk is increased, because this may aid in identifying high-risk postmenopausal women in the clinical setting.\nAcknowledgements: Author’s contribution: T.M. and O.H.F. conceived and designed the study. T.M. run the analysis. W.B. designed and executed the search strategies. T.M., J.N. and Dr Wanes Kazanjian screened title/abstract, obtained full text, determined eligibility of articles and participated in data extraction. T.M. participated in data synthesis/analysis and interpretation of the data. T.M. and O.H.F. drafted the final manuscript. T.M. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed to the critical revision of the manuscript and approved the final version. The authors thank Dr Wanes Kazanjian, Erasmus Medical Center, for reviewing the abstract.\nFunding/Support: This study was sponsored and funded by Metagenics Inc.\nRole of the Funder/Sponsor: Metagenics Inc. had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript. The funder/sponsor did not have the ability to veto publication of study results. Disclosure statement: T.M., L.J. and O.H.F. work in ErasmusAGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd.), Metagenics Inc. and AXA. T.M. and L.J. reported receiving research support from Metagenics.Inc. JN has been financially supported by Erasmus Mundus Western Balkans (ERAWEB), a project funded by the European\n17\nCommission. M.K. is supported by the AXA Research Fund. O.H.F. reported receiving grants or research support from Metagenics Inc. These funding sources had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript. C. Meun, W.M. Bramer, A. Hofman and J.S.E. Laven have nothing to disclose.\n18"
    }, {
      "heading" : "Legend for Figure 1",
      "text" : "Relative risks of type 2 diabetes comparing top vs. bottom thirds of baseline plasma sex hormone-binding globulin. The summary estimates presented were calculated using random effects models ( D+L) and fixed effects ( I-V ); Size of data markers are proportional to the inverse of the variance of the odds ratio; CI confidence interval (bars). X2= 36.2, I2=77.9%; P < 0.001\n26"
    }, {
      "heading" : "Legend for Figure 2",
      "text" : "Relative risks of type 2 diabetes comparing top vs. bottom thirds of baseline plasma total and free testosterone levels. The summary estimates presented were calculated using random effects models ( D+L) and fixed effects ( I-V ); Size of data markers are proportional to the inverse of the variance of the odds ratio; CI confidence interval (bars). A) X2= 8.6, I2=53.8%; P =0.07; B) X2= 15.5, I 2 =80.7%; P =0.001\n27"
    }, {
      "heading" : "Legend for Figure 3",
      "text" : "Relative risks of type 2 diabetes comparing top vs. bottom thirds of baseline plasma total and free estradiol levels. The summary estimates presented were calculated using random effects models ( D+L) and fixed effects ( I-V ); Size of data markers are proportional to the inverse of the variance of the odds ratio; CI confidence interval (bars). A) X2= 8.91, I2=55.1%; P =0.06; B) X2= 5.26, I 2 =81.0%; P =0.02\nRelative risks of type 2 diabetes comparing top vs. bottom thirds of baseline plasma sex hormone-binding globulin. The summary estimates presented were calculated using random effects models ( D+L) and fixed effects ( I-V ); Size of data markers are proportional to the inverse of the variance of the odds ratio; CI\nconfidence interval (bars). X2= 36.2, I2=77.9%; P < 0.001\n124x71mm (300 x 300 DPI)\nRelative risks of type 2 diabetes comparing top vs. bottom thirds of baseline plasma total and free testosterone levels. The summary estimates presented were calculated using random effects models ( D+L) and fixed effects ( I-V ); Size of data markers are proportional to the inverse of the variance of the odds\nratio; CI confidence interval (bars). A) X2= 8.6, I2=53.8%; P =0.07; B) X2= 15.5, I2=80.7%; P =0.001\n223x323mm (300 x 300 DPI)\nRelative risks of type 2 diabetes comparing top vs. bottom thirds of baseline plasma total and free estradiol levels. The summary estimates presented were calculated using random effects models ( D+L) and fixed effects ( I-V ); Size of data markers are proportional to the inverse of the variance of the odds ratio; CI\nconfidence interval (bars). A) X2= 8.91, I2=55.1%; P =0.06; B) X2= 5.26, I2=81.0%; P =0.02\n223x319mm (300 x 300 DPI)\nOnline Supplemental Material"
    }, {
      "heading" : "Included in the Online Supplemental Material:",
      "text" : "S1 Figure Flowchart of studies investigating the association between endogenous sex hormones and the risk of type 2 diabetes.\nS2 Figure Assessment of small study effects by funnel plots and Egger’s test in prospective studies of sexhormone binding globulin, sex hormones and type 2 diabetes.\nS1 Table Sensitivity analysis of sex and the risk of type 2 diabetes postmenopausal women, the Rotterdam Study.\nS2 Table Characteristics of the included studies that assessed the association of sex hormones with the risk of type 2 diabetes\nS3 Table . Assays used to assess sex hormones and sex hormone binding globulin across the studies included in the systematic review\nS4 Table. Pooled relative risks for type 2 diabetes by characteristic of study participants\nS1 Appendix Potential confounding variables\nS2 Appendix PRISMA 2009 checklist S3 Appendix MOOSE checklist S4 Appendix Search strategy S5 Appendix Data extraction, quality assessment and data synthesis S6 Appendix References of the articles included in the Systematic Review\nS1 Figure Flowchart of studies investigating the association between endogenous sex hormones and the risk of type 2 diabetes.\nRecords identified through database\nsearching (n = 3209)\nRecords screened\n(n =3209)\nRecords excluded based on\ntitle and abstract\n(n =3187)\nRecords given full text\ndetailed assessment\n(n = 23)\nFull-text articles excluded\n(n = 8)\n• Not the appropriate exposure or outcome (n=6) • Case-control study (n=2)\nArticle included (n=15)\nbased on 12 unique studies\n( 13 unique studies\nincluding Rotterdam\nStudy)\nS2 Figure Assessment of small study effects by funnel plots and Egger’s test in prospective studies of of sex-hormone binding globulin, sex hormones and type 2 diabetes.\nThe dotted lines show 95% confidence intervals around the overall summary estimate calculated using a fixed effect model; p-values for bias calculated using Egger’s test was 0.014, 0.08 and 0.18 for sex hormone-binding globulin, total testosterone and total estradiol, respectively.\nSex hormone-binding globulin Total testosterone Total estradiol\nS1 Table Sensitivity analysis of sex and the risk of type 2 diabetes postmenopausal women, the Rotterdam Study.\nMultivariable model adjusted for variables in model 3 of Table 2.\na Values are + 1 log increase b Values are per 1 unit increase c Results are adjusted for variables in model 3 of Table 2 d P-interaction >0.05 e P-interaction=0.019 k P-interaction=0.03\nSex hormone-binding\nglobulin a\nTotal Testosterone a Estradiol b Free androgen index a\nMultivariable model 0.66 (0.51-0.86) 0.93 (0.76-1.14) 1.002 (1.001-1.004) 1.15 (0.85-1.54) Multivariable model + waist\ncircumference 0.69 (0.53-0.90) 0.96 (0.78-1.19) 1.003 (1.001-1.005) 1.11 (0.92-1.33) Multivariable model + HDL + TG\n+ LDL 0.72 (0.55-0.95) 0.94 (0.76-1.16) 1.003 (1.001-1.004) 1.07 (0.89-1.29) Multivariable model + serum\nthyroid stimulating hormone 0.66 (0.51-0.87) 0.89 (0.73-1.09) 1.002 (1.001-1.004) 1.11 (0.93-1.33) Multivariable model + physical\nactivity 0.66 (0.50-0.86) 0.89 (0.73-1.09) 1.003 (1.001-1.004) 1.12 (0.94-1.34) Multivariable model + menopause\ntype (surgical vs. natural) 0.65 (0.50-0.85) 0.89 (0.72-1.08) 1.003 (1.001-1.004) 1.12 (0.94-1.34) Multivariable model + number of\npregnancies of at least 6 months 0.65 (0.51-0.85) 0.94 (0.76-1.15) 1.003 (1.001-1.004) 1.12 (0.94-1.34) Multivariable model excluding the\nfirst 3 years of follow-up 0.68 (0.51-0.91) 0.98 (0.79-1.23) 1.003 (1.001 -1.005) 1.13 (0.93-1.37) BMI (kg/m 2 ) c <25 0.50 (0.28-0.91) d 0.90 (0.56-1.45) d 1.003 (1.001-1.006) d 1.18 (0.78-1.78) d 25-29.9 0.80 (0.54-1.18) 1.20 (0.88-1.62) 1.003 (1.00-1.006) 1.22 (0.94-1.58) ≥30 0.76 (0.48-1.22) 0.86 (0.59-1.24) 1.001 (1.00-1.005) 0.99 (0.72-1.36) Time since menopause c <15 0.84 (0.47-1.50) d 1.26 (0.84-1.89) e 1.004 (1.001-1.007) d 1.22 (0.86-1.73) k 15-25 0.78 (0.51-1.19) 1.01 (0.73-1.40) 1.002 (0.998 -1.006) 1.09 (0.83-1.44) >25 0.46 (0.28-0.75) 0.78 (0.55-1.10) 1.003 (0.996 -1.01) 1.08 (0.79-1.48)\nS2 Table Characteristics of the included studies that assessed the association of sex hormones with the risk of type 2 diabetes\nLead Author, Publication Date\nName of study or source of participants\nLocation\nYear of baseline survey\nBaseline age range/ average age (years)\nStudy design\nFollow\nup years\nTotal\nparticipants\nNo. of\nstudy\nevents\nMenopausal Status\nCovariates adjusted for\nStudy quality*\nOh 2002 RBS USA 1984-1987 72.4 ± 6.14 Case-cohort 8 233 17 Postmenopausal Age, BMI, systolic\nblood pressure, 7\nChen BH et al.2012 Ding 2007 and 2009\nWHI-OS USA 1994-1998 61.1 ± 5.2 Case-cohort 5.9\n(median) 1928 642 Postmenopausal\nAge, race/ethnicity, clinical center, time of blood flow, duration of follow-up, postmenopausal hormone therapy, physical activity, smoking status, alcohol intake, history of hypertension, family history of diabetes, body mass index, Creactive protein, HOMA-IR, testosterone, LDL, HDL-cholesterol, glycated haemoglobin.\n8\nLead Author, Publication Date\nName of study or source of participants\nLocation\nYear of baseline survey\nBaseline age range/ average age (years)\nStudy design\nFollow\nup years\nTotal\nparticipants\nNo. of\nstudy\nevents\nMenopausal Status\nCovariates adjusted for\nStudy quality*\nKalyani 2009 MESA USA 2000-20002 65.2 ± 9.0 Prospective 6 1612 116 Postmenopausal\nAge, race/ethnicity, education, income, family history of diabetes, examination site, BMI, HOMA-IR, LDL, HDL, triglycerides, use of lipid-lowering medications, systolic blood pressure, antihypertensive medication, total daily caloric intake, physical activity, smoking, IL-6, CRP, age at menopause, years since menopause, type of menopause, age at first live birth, five or more live births, and past use of hormone replacement therapy r oral contraceptive pills.\n9\nOnat 2010 TARFS Turkey 48.4 ± 11.7 Case-cohort 9 1067 202 Pre- and post-\nmenopausal\nAge, BMI, C-reactive protein, HDLcholesterol, lipid lowering drugs and Apolipoprotein A-1\n7\nHaffner 1993 SAHS USA 1979-1982 25-64 Case-cohort 8 109 38 Pre- and post-\nmenopausal Fasting glucose and\ninsulin 7\nSoriguer 2011 PCS Italy 1995-1997 36 ± 23 Case-cohort 11 691 106* Pre- and post-\nmenopausal Age, body mass index\nand waist circumference 8\nLead Author, Publication Date\nName of study or source of participants\nLocation\nYear of baseline survey\nBaseline age range/ average age (years)\nStudy design\nFollow\nup years\nTotal\nparticipants\nNo. of\nstudy\nevents\nMenopausal Status\nCovariates adjusted for\nStudy quality*\nGambineri 2012 NA Italy 1978-1999 23.4 ± 6.3 Prospective 16.9 255 42 Pre-menopausal\nAge, BMI, fasting glucose, waist to hip ratio, systolic blood pressure, diastolic blood pressure, fasting insulin, HbA1C, total cholesterol, HDLcholesterol, triglycerides, luteinizing hormone, folliclestimulating hormone, estradiol, testosterone, SHBG\n8\nLindstedt G et al. 1991 NA Sweden 1968-1969 38-60 Prospective 12 1462 43 Pre and postmenopausal NA 7 BoydWoschinko 2007 NA USA 36-43 Case-cohort 8 119 10 Pre-menopausal NA 5 Okubo M et al. 1999 Medical survey Hawaii and USA 1992-1993 65.4 ± 0.5 Prospective 3 280 23 Postmenopausal Age, body mass index\nand waist to hip ratio 6\nFenske B et al. 2015\nStudy of Health in Pomerania Germany 1997-2001 48.8 ± 16.2 Prospective 5 1925 202* Pre and postmenopausal\nAge, waist circumference, physical inactivity and alcohol consumption.\n8\nLead Author, Publication Date\nName of study or source of participants\nLocation\nYear of baseline survey\nBaseline age range/ average age (years)\nStudy design\nFollow\nup years\nTotal\nparticipants\nNo. of\nstudy\nevents\nMenopausal Status\nCovariates adjusted for\nStudy quality*\nHu J et al. 2015 EIMDS China 2008 60 ± 11.1\nProspective, nested casecontrol\n5 174 87 Postmenopausal\nBMI, systolic blood pressure, diastolic blood pressure, current smoking, alcohol use, hypertension, exercise frequency, family history of T2D, fasting plasma glucose, total cholesterol, highdensity lipoprotein cholesterol and low density lipoprotein cholesterol.\n8\nMather 2015 DPP USA 1997 50.9 ± 7.9 Prospective 3 1930 ND Pre and\npostmenopausal\nAge, ethnicity, smoking, alcohol consumption, leisure activity, waist circumference, fasting insulin and insulinogenic index\n7\nTotal 14,902 1912\nBMI, Body mass index; DPP, Diabetes Prevention Program; EIMDS, The Environment, Inflammation and Metabolic Diseases Study; MESA, Multi-Ethnic Study of Atherosclerosis; ND, not determined; PCS, Pizarra Cohort Study; RBS, Rancho Bernardo Study; SAHS, San Antonio Heart Study; TARFS, Turkish Adult Risk Factor Study; WHS, Women Health’s Study *approximation\nS3 Table . Assays used to assess sex hormones and sex hormone binding globulin across the studies included in the systematic review\nAuthor, year of publication Estradiol Testosterone Sex hormone binding globuline Oh 2002 Radioimmunoassay;\nBioavailable estradiol was determined using a modification of the ammonium-sulfate precipitation method of Tremblay and Dube.\nRadioimmunoassay; Bioavailable testosterone was determined using a modification of the ammonium-sulfate precipitation method of Tremblay and Dube. NA\nChen BH et al.2012 Ding 2007 and 2009\nChemiluminescent immunoassays (Elecsys Autoanalyzer 2010; Roche Diagnostics, Indianapolis, IN, USA. Free oestradiol and free testosterone were calculated via the Sodergard method.\nChemiluminescent immunoassays (Elecsys Autoanalyzer 2010; Roche Diagnostics, Indianapolis, IN, USA. Free oestradiol and free testosterone were calculated via the Sodergard method.\nChemiluminescent immunoassays (Elecsys Autoanalyzer 2010; Roche Diagnostics, Indianapolis, IN, USA\nKalyani 2009 An ultrasensitive RIA kit from Diagnostic Systems Laboratories\n(Webster, TX).\nMeasured directly using RIA kits. Concentrations of free T, SHBG-bound T, and albumin-bound T were calculated according to the method of So¨ dergård et al., allowing for determination of bioavailable T as the sum of SHBG-bound T and albuminbound T. Chemiluminescent enzyme immunometric assay using Immulite kits obtained from Diagnostic Products Corp\nOnat 2010 NA NA Chemiluminescent immunometric\nmethod using Roche kits and Elecsys 1010 immunautoanalyzer (Roche Diagnostics, Mannheim, Germany).\nHaffner 1993 NA NA Immunoradiometric assay technique\n(Diagnostic Products Corp, Los Angelos, CA)\nSoriguer 2011\nNA Enzyme immunoassay (ELISA) (DRG\nInstruments GMBH, Bioavailable testosterone (nM) (bioT) was calculated according to Morris et al. Marburg, Germany)\nEnzyme immunoassay (ELISA) (DRG Instruments GMBH, Marburg, Germany)\nNA, not available.\nGambineri 2012 NA NA Not defined Lindstedt G et al. 1991 Immunoradiometric assay technique Boyd-Woschinko 2007 NA NA Radioimmunoassay Okubo M et al. 1999 NA NA IRMA kit (Orion Diagnostica,\nFinland).\nFenske B et al. 2015 NA Liquid chromatography-tandem\nmass spectrometry (LC-MS). Free testosterone (fT) was calculated as a relation between measured TT and SHBG levels for a standard average albumin concentration of 4.3 g/dL.\nAdvia Centaur (Siemens, Eschborn, Germany)\nS4 Table. Pooled relative risks for type 2 diabetes by characteristic of study participants.\na P-value for heterogeneity was evaluated using random effects meta-regression.\nSubgroups by Study Characteristics\nMenopause status Number\nof studies\nNumber of participants\nNumber of type 2 diabetes cases\nRelative Risk (95%\nCI)\nP-value for heterogeneity a\nAssociation between sex hormone binding globulin and risk of type 2 diabetes\nMenopause status Premenopause 1 119 10 0.12 (0.01, 1.22) 0.91\nPre- and postmenopause 3 3101 442 0.41 (0.13, 1.28) Postmenopause 5 7056 1271 0.45 (0.28, 0.72)\nNumber of participants <1000 4 627 177 0.20 (0.04, 0.87) 0.39\n≥1000 5 9649 1546 0.44 (0.30, 0.66)\nLocation Europe 4 6334 830 0.64 (0.47, 0.88) 0.08\nAmerica 4 3768 806 0.24 (0.09, 0.68) Asia 1 174 87 0.14(0.10, 0.74)\nAssociation between total testosterone and risk of type 2 diabetes\nMenopause status Pre- and postmenopause 1 1925 202 0.90 (0.41, 1.98) 0.46\nPostmenopause 4 5452 1130 1.58 (0.78, 3.20)\nNumber of participants <1000 4 627 177 1.77 (0.79, 3.94) 0.44\n≥1000 5 9649 1546 1.19 (0.62, 2.29)\nLocation Europe 2 5042 586 0.88 (0.68, 1.14) 0.02\nAmerica 2 2161 656 2.08 (1.05, 4.15) Asia 1 174 87 3.51 (0.62, 23.10)\nS1 Appendix Potential confounding variables Information on current health status, medical history, medication use, smoking behaviour, and socioeconomic status was obtained at baseline for both studies. During the home interview, women were asked a special section of questions pertaining to menopausal status. One set of questions dealt with timing of the last menstrual period, gathering information on whether the respondent had a natural menstrual period within the 12 months, the past 3 months, and the age at last period for women who had no period for at least 3 months. One question addressed period regularity and the number of menstrual cycles. Postmenopausal women were defined women who reported absence of menstrual periods for 12 months. Participants were asked whether they were currently smoking cigarettes, cigars, or pipes. Alcohol intake was assessed in grams of ethanol per day. History of cardiovascular disease was defined as a history of coronary heart diseases (myocardial infarction, revascularization, coronary artery bypass graft surgery or percutaneous coronary intervention) and was verified from the medical records of the general practitioner. Blood pressure was measured in the sitting position at the right upper arm with a random-zero-sphygmomanometer. Physical height (m) and body weight (kg) were measured at baseline with the participants standing without shoes and heavy outer garments. Body mass index (BMI) was calculated as weight divided by height squared (kg/m2). All biochemical parameters were assessed in fasting serum. Thyroid stimulating hormone (TSH) was measured on the Vitros Eci (Ortho Diagnostics). Insulin, glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and C-reactive protein (CRP) were measured on the COBAS 8000 Modular Analyzer (Roche Diagnostics GmbH). The corresponding interassay coefficients of variations are the following: TSH<13.2%, insulin <8%, glucose <1.4%, lipids <2.1% and CRP <16.9%. Physical activity was assessed with an adapted version of the Zutphen Physical Activity Questionnaire1. Every activity mentioned in the questionnaire was attributed a MET-value according to the 2011 2 .The questionnaire contained questions on walking, cycling, gardening, diverse sports, hobbies and on housekeeping. Total time spend on physical activity was calculated as the sum of minutes per week for each type of activity.\nS5 Appendix. Data extraction and quality assessment Data were extracted by two independent reviewers and a consensus was reached with involvement of a third. A predesigned data abstraction form was used to extract relevant information. This included questions on study size; study design; baseline population; location; age at baseline; duration of follow-up (for cohort studies) and menopausal status. Additionally, in the case of multiple publications, the most up-to-date or comprehensive information was included. Study quality was assessed based on the nine-star Newcastle–Ottawa Scale (NOS) 3 using three pre-defined domains namely: selection of participants (population representativeness), comparability (adjustment for confounders), and ascertainment of outcomes of interest. The NOS assigns a maximum of four points for selection, two points for comparability, and three points for outcome. Nine points on the NOS reflects the highest study quality. Data synthesis and analysis For the meta-analysis, we used the risk estimates of the most adjust models reported by each study. To enable a consistent approach for the metaanalysis, we used previously described methods 4 to transform RR estimates for associations between sex hormones with T2D risk which were often differentially reported by each study (for example, per unit change, per one standard deviation change, or comparing quarters or thirds, and other groupings), and therefore, to consistently correspond to comparison of the top third versus the bottom of the baseline distribution by sex hormone levels in each study. Briefly, we transformed the log RR by assuming a normal distribution, with the comparison between extreme thirds being equivalent to 2.18 times the log risk ratio for one standard deviation increases (or equivalently as 2.18/2.54 time the log RR for a comparison of\nextreme quarters). We calculated standard error of the log RR by using published CIs and standardised them in the same way. Hazard ratios, RRs, and odds ratios were assumed to approximate the same measure of RR. The inverse variance weighted method was used to combine relative risks to produce a pooled relative risk using random-effects models to allow for between study heterogeneity. Also, additionally we reported the estimates using fixed effect models. Heterogeneity was assessed using the Cochrane χ 2 statistic and the I 2 statistic. Publication bias was evaluated through a funnel plot and Egger’s test. Menopause status, location and number of participants were pre-specified as characteristics for assessment of heterogeneity, and was evaluated using stratified analyses and random effects metaregression for the meta-analysis that included 5 or more studies 5 . All tests were two-tailed and p-values of 0.05 or less were considered significant. STATA release 12 (Stata Corp, College Station, Texas) was used for all statistical analyses.\nREFERENCES:\n1. Caspersen CJ, Bloemberg BP, Saris WH, Merritt RK, Kromhout D (1991) The prevalence of selected physical activities and their relation with coronary heart\ndisease risk factors in elderly men: the Zutphen Study, 1985. Am J Epidemiol 133: 1078-1092.\n2. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR, Jr., et al. (2011) 2011 Compendium of Physical Activities: a second update of codes and MET\nvalues. Med Sci Sports Exerc 43: 1575-1581.\n3. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol.\n2010;25(9):603-605.\n4. Chene G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol.\n1996;144(6):610-621.\n5. Thompson SG, Sharp SJ: Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999;18:2693-2708\nS2 Appendix PRISMA 2009 checklist\nSection/topic # Checklist item Reported on\npage #\nTITLE Title 1 Identify the report as a systematic review, meta-analysis, or both. 1 ABSTRACT Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria,\nparticipants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.\n3-4\nINTRODUCTION Rationale 3 Describe the rationale for the review in the context of what is already known. 5 Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes,\nand study design (PICOS).\n5\nMETHODS Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration\ninformation including registration number.\n9\nEligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language,\npublication status) used as criteria for eligibility, giving rationale.\n9\nInformation sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional\nstudies) in the search and date last searched.\n9-10\nSearch 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. * (S4\nAppendix)\nStudy selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in\nthe meta-analysis).\n9-10\nData collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for\nobtaining and confirming data from investigators.\n10-11\nData items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications\nmade.\n10-11\nRisk of bias in individual studies\n12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the\nstudy or outcome level), and how this information is to be used in any data synthesis.\n10\nSection/topic # Checklist item Reported on\npage #\nSummary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 10-11 Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for\neach meta-analysis.\n10-11\nRisk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within\nstudies).\n10-11\nAdditional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were\npre-specified.\nNA\nRESULTS Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage,\nideally with a flow diagram.\n13, S1 Figure.\nStudy characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the\ncitations.\n13 and S2\nTable\nRisk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 13 and\nTable S2\nResults of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b)\neffect estimates and confidence intervals, ideally with a forest plot.\n13-14\nSynthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. 13-14 Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). 14 Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). 14 DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups\n(e.g., healthcare providers, users, and policy makers).\n15\nLimitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified\nresearch, reporting bias).\n17-18\nConclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 15-19 FUNDING\nFunding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic\nreview.\n2-3\nS3 Appendix MOOSE checklist\nCriteria Brief description of how the criteria were handled in the meta-\nanalysis\nReporting of background should include √ Problem definition The menopause transition is marked by changes in hormonal\npatterns, including a marked decline in endogenous estradiol levels, leading to a period of relative androgen excess1. This shift in hormonal balance contributes to an increase in visceral adiposity that is associated with glycemic traits, and therefore may be associated with the risk of type 2 diabetes (T2D). To date, no large studies have examined simultaneously the association of T2D with SHBG, T and E in healthy postmenopausal women.\n√ Hypothesis statement Endogenous sex hormone levels are associated with the risk of T2D. √ Description of study outcomes Incidence of T2D √ Type of exposure or intervention\nused\nTotal estradiol (TE), total testosterone (TT) and sex-hormone binding globulin (SHBG) were measured. Free androgen index (FAI) was calculated as ratio of TT to SHBG concentration\n√ Type of study designs used Studies were sought if they (i) were observational cohort, case-\ncohort studies, or prospective nested case control studies; (ii) had reported on at least one of the sex hormones as exposures: SHBG, TT, BT, TE and bioavailable estradiol (BE); and (iii) had assessed associations with risk of T2D in women (pre and postmenopausal).\n√ Study population Only studies carried out in women. Reporting of search strategy should include √ Qualifications of searchers The credentials of the investigators are indicated in the authors list. √ Search strategy, including time\nperiod included in the synthesis and keywords\nSearch strategy and time periods are detailed in page 8 of the manuscript and in S4 Appendix.\n√ Databases and registries searched Embase, Medline, Web-of-Science, PubMed, Cochrane and Google\nScholar.\n√ Search software used, name and We did not employ a search software. EndNote was used to merge\nversion, including special features retrieved references and eliminate duplicates.\n√ Use of hand searching We hand-searched bibliographies of retrieved papers and systematic\nreviews for additional references.\n√ List of citations located and those\nexcluded, including justifications\nDetails of the literature search process are outlined in the flow chart. Citations for the included studies are enclosed with the S1 Table and S5 Appendix. The citation list for excluded studies is available upon request.\n√ Method of addressing articles\npublished in languages other than English\nWe placed no restrictions on language; local scientists fluent in the original language of the article were contacted for translation.\n√ Method of handling abstracts and\nunpublished studies\nNo unpublished studies were identified\n√ Description of any contact with\nauthors\nWe contacted authors of papers if we could not find full texts.\nReporting of methods should include √ Description of relevance or\nappropriateness of studies assembled for assessing the hypothesis to be tested\nDetailed inclusion and exclusion criteria were described in the methods section.\n√ Rationale for the selection and\ncoding of data\nA predesigned data abstraction form was used to extract relevant information. This included questions on study size; study design; baseline population; location; age at baseline; duration of follow-up (for cohort studies) and menopausal status.\n√ Assessment of confounding Confounding was not assessed. √ Assessment of study quality,\nincluding blinding of quality assessors; stratification or regression on possible predictors of study results\nStudy quality was assessed based on the nine-star Newcastle– Ottawa Scale(NOS)23 using three pre-defined domains namely: selection of participants (population representativeness), comparability (adjustment for confounders), and ascertainment of outcomes of interest. The NOS assigns a maximum of four points for selection, two points for comparability, and three points for outcome. Nine points on the NOS reflects the highest study quality.\n√ Assessment of heterogeneity Heterogeneity was assessed using the Cochrane χ2 statistic and the\nI2 statistic.\n√ Description of statistical methods in\nsufficient detail to be replicated\nDescription of methods of systematic review and assessment of publication bias are detailed in the methods.\n√ Provision of appropriate tables and We included 2 main tables, 3 main Figures, 2 supplementary tables\ngraphics and 2 supplementary Figures.\nReporting of results should include √ Graph summarizing individual study\npublication of study results. Acknowledgements: TM, LJ and OHF work in ErasmusAGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd.), Metagenics Inc. and AXA. TM and LJ reported receiving research support from Metagenics.Inc. JN has been financially supported by Erasmus Mundus Western Balkans (ERAWEB), a project funded by the European Commission. MK is supported by the AXA Research Fund. OHF reported receiving grants or research support from Metagenics Inc. These funding sources had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript. C. Meun, W.M. Bramer, A. Hofman and J.S.E. Laven have nothing to disclose.\nS4 Appendix Search strategy\nEmbase.com\n('sex hormone'/de OR androgen/de OR 'androgen blood level'/de OR 'androgen deficiency'/de OR testosterone/de OR 'testosterone blood level'/de OR 'sex hormone binding globulin'/de OR estradiol/de OR 'estradiol blood level'/de OR hypogonadism/exp OR 'gonad dysfunction'/de OR 'ovary insufficiency'/exp OR 'testis function'/de OR 'hyperandrogenism'/exp OR (((sex OR sexual OR gonad* OR testicular* OR ovar*) NEXT/3 hormone*) OR androgen* OR hyperandrogen* OR hypoandrogen* OR testosterone* OR estradiol* OR oestradiol* OR hypogonad* OR hypergonad* OR ((gonad OR testis OR testes OR testicular OR ovar*) NEAR/3 (dysfunction* OR insufficien* OR failure* OR hypofunct* OR function*))):ab,ti) AND ('non insulin dependent diabetes mellitus'/exp OR (((diabet* OR dm) NEAR/3 ('type 2' OR type2 OR 'type ii' OR 'non insulin' OR noninsulin OR 'adult onset' OR 'slow onset' OR 'maturity onset')) OR T2DM OR dmt2 OR dm2 OR T2-DM OR dm-t2 OR dm-2 OR niddm OR nid-dm):ab,ti) NOT ([animals]/lim NOT [humans]/lim) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim)\nMedline ovid\n(\"Gonadal Steroid Hormones\"/ OR androgens/ OR testosterone/ OR \"Sex Hormone-Binding Globulin\"/ OR estradiol/ OR hypogonadism/ OR \"hyperandrogenism\"/ OR (((sex OR sexual OR gonad* OR testicular* OR ovar*) ADJ3 hormone*) OR androgen* OR hyperandrogen* OR hypoandrogen* OR testosterone* OR estradiol* OR oestradiol* OR hypogonad* OR hypergonad* OR ((gonad OR testis OR testes OR testicular OR ovar*) ADJ3 (dysfunction* OR\ninsufficien* OR failure* OR hypofunct* OR function*))).ab,ti.) AND (\"Diabetes Mellitus, Type 2\"/ OR (((diabet* OR dm) ADJ3 (\"type 2\" OR type2 OR \"type ii\" OR \"non insulin\" OR noninsulin OR \"adult onset\" OR \"slow onset\" OR \"maturity onset\")) OR T2DM OR dmt2 OR dm2 OR T2-DM OR dm-t2 OR dm-2 OR niddm OR nid-dm).ab,ti.) NOT (exp animals/ NOT humans/) NOT (letter OR news OR comment OR editorial OR congresses OR abstracts).pt.\nCochrane\n((((sex OR sexual OR gonad* OR testicular* OR ovar*) NEXT/3 hormone*) OR androgen* OR hyperandrogen* OR hypoandrogen* OR testosterone* OR estradiol* OR oestradiol* OR hypogonad* OR hypergonad* OR ((gonad OR testis OR testes OR testicular OR ovar*) NEAR/3 (dysfunction* OR insufficien* OR failure* OR hypofunct* OR function*))):ab,ti) AND ((((diabet* OR dm) NEAR/3 ('type 2' OR type2 OR 'type ii' OR 'non insulin' OR noninsulin OR 'adult onset' OR 'slow onset' OR 'maturity onset')) OR T2DM OR dmt2 OR dm2 OR T2-DM OR dm-t2 OR dm-2 OR niddm OR nid-dm):ab,ti)\nWeb-of-science\nTS=(((((sex OR sexual OR gonad* OR testicular* OR ovar*) NEAR/2 hormone*) OR androgen* OR hyperandrogen* OR hypoandrogen* OR testosterone* OR estradiol* OR oestradiol* OR hypogonad* OR hypergonad* OR ((gonad OR testis OR testes OR testicular OR ovar*) NEAR/2 (dysfunction* OR insufficien* OR failure* OR hypofunct* OR function*)))) AND ((((diabet* OR dm) NEAR/2 (\"type 2\" OR type2 OR \"type ii\" OR \"non insulin\" OR noninsulin OR \"adult onset\" OR \"slow onset\" OR \"maturity onset\")) OR T2DM OR dmt2 OR dm2 OR T2-DM OR dm-t2 OR dm-2 OR niddm OR nid-dm)) NOT ((animal* OR rat OR rats\nOR mouse OR mice OR murine OR nonhuman* OR primate*) NOT (human* OR patient*))) AND DT=(article)\nPubmed publisher\n(\"Gonadal Steroid Hormones\"[mh] OR androgens[mh] OR testosterone[mh] OR \"Sex HormoneBinding Globulin\"[mh] OR estradiol[mh] OR hypogonadism[mh] OR \"hyperandrogenism\"[mh] OR (((sex OR sexual OR gonad*[tiab] OR testicular*[tiab] OR ovar*[tiab]) AND hormone*[tiab]) OR androgen*[tiab] OR hyperandrogen*[tiab] OR hypoandrogen*[tiab] OR testosterone*[tiab] OR estradiol*[tiab] OR oestradiol*[tiab] OR hypogonad*[tiab] OR hypergonad*[tiab] OR ((gonad OR testis OR testes OR testicular OR ovar*[tiab]) AND (dysfunction*[tiab] OR insufficien*[tiab] OR failure*[tiab] OR hypofunct*[tiab] OR function*[tiab])))) AND (\"Diabetes Mellitus, Type 2\"[mh] OR (((diabet*[tiab] OR dm) AND (\"type 2\" OR type2 OR \"type ii\" OR \"non insulin\" OR noninsulin OR \"adult onset\" OR \"slow onset\" OR \"maturity onset\")) OR T2DM OR dmt2 OR dm2 OR T2-DM OR dm-t2 OR dm-2 OR niddm OR nid-dm)) NOT (animals[mh] NOT humans[mh]) NOT (letter[pt] OR news[pt] OR comment[pt] OR editorial[pt] OR congresses[pt] OR abstracts[pt]) AND publisher[sb]\nGoogle scholar\n\"sex|gonadal|testicular|ovarian hormone|hormones\"|androgen|hyperandrogenism|hypoandrogenism|testosterone|estradiol|hypogo nadism diabetes \"type 2|ii\"|\"non insulin\"|noninsulin|\"adult onset\"|\"slow onset\"|\"maturity onset\"\nS5 Appendix References of the articles included in the Systematic Review\n1. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older\nmen and women: The Rancho Bernardo Study. Diabetes Care 2002;25(1):55-60.\n2. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, et al. Sex hormone-binding globulin and risk of type 2 diabetes in\nwomen and men. New England Journal of Medicine 2009;361(12):1152-63.\n3. Chen BH, Brennan K, Goto A, Song Y, Aziz N, You NC, et al. Sex hormone-binding globulin and risk of clinical diabetes in\nAmerican black, Hispanic, and Asian/Pacific Islander postmenopausal women. Clin Chem 2012;58(10):1457-66.\n4. Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Bertoni A, et al. The association of endogenous sex hormones, adiposity,\nand insulin resistance with incident diabetes in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2009;94(11):4127-35.\n5. Onat A, Hergenc G, Bulur S, Ugur M, Kucukdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently\npredicting incident type-2 diabetes among Turks. International Journal of Cardiology 2010;142(1):72-79.\n6. Haffner SM, Valdez RA, Morales PA, Hazuda HP, Stern MP. Decreased sex hormone-binding globulin predicts noninsulin-\ndependent diabetes mellitus in women but not in men. Journal of Clinical Endocrinology and Metabolism 1993;77(1):56-60.\n7. Soriguer F, Rubio-Martin E, Fernandez D, Valdes S, Garcia-Escobar E, Martin-Nunez GM, et al. Testosterone, SHBG and risk of\ntype 2 diabetes in the second evaluation of the Pizarra cohort study. European Journal of Clinical Investigation 2012;42(1):79- 85.\n8. Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L, et al. Polycystic ovary syndrome is a risk factor for type 2\ndiabetes: Results from a long-term prospective study. Diabetes 2012;61(9):2369-74.\n9. Lindstedt G, Lundberg PA, Lapidus L, Lundgren H, Bengtsson C, Bjorntorp P. Low sex-hormone-binding globulin concentration as\nindependent risk factor for development of NIDDM: 12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes 1991;40(1):123-28.\n10. Boyd-Woschinko G, Kushner H, Falkner B. Androgen excess is associated with insulin resistance and the development of diabetes\nin African American women. Journal of the cardiometabolic syndrome 2007;2(4):254-59.\n11. Okubo M, Tokui M, Egusa G, Yamakido M. Association of sex hormone-binding globulin and insulin resistance among Japanese-\nAmerican subjects. Diabetes Res Clin Pract 2000;47(1):71-5.\n12. Fenske B, Kische H, Gross S, Wallaschofski H, Volzke H, Dorr M, et al. Endogenous androgens and sex hormone-binding\nglobulin in women and risk of metabolic syndrome and type 2 diabetes. J Clin Endocrinol Metab 2015:jc20152546.\n13. Hu J, Zhang A, Yang S, Wang Y, Goswami R, Zhou H, et al. Combined effects of sex hormone-binding globulin and sex\nhormones on risk of incident type 2 diabetes. J Diabetes 2015.\n14. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S. Plasma sex steroid hormones and risk of developing type 2 diabetes in\nwomen: A prospective study. Diabetologia 2007;50(10):2076-84."
    } ],
    "references" : [ {
      "title" : "Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis",
      "author" : [ "BM Atsma F", "DE Grobbee", "YT. van der Schouw" ],
      "venue" : "Menopause",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2006
    }, {
      "title" : "Genazzani AR: Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women",
      "author" : [ "M Gambacciani", "M Ciaponi", "B Cappagli", "L Piaggesi", "L de Simone", "R Orlandi" ],
      "venue" : "(vol 82,",
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 1997
    }, {
      "title" : "Relative androgen excess and increased cardiovascular risk after menopause: A hypothesized relation",
      "author" : [ "YM Liu", "JZ Ding", "TL Trudy", "JC Longenecker", "FJ Nieto", "SH Golden", "M Szklo" ],
      "venue" : "Am J Epidemiol",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 2001
    }, {
      "title" : "Age at Menopause, Reproductive Life Span, and Type 2 Diabetes Risk. Diabetes Care 2013;36:1012-1019",
      "author" : [ "JS Brand", "YT van der Schouw", "NC Onland-Moret", "SJ Sharp", "KK Ong", "KT Khaw", "E Ardanaz", "P Amiano", "H Boeing", "MD Chirlaque", "F Clavel-Chapelon", "FL Crowe", "B de Lauzon-Guillain", "EJ Duell", "G Fagherazzi", "PW Franks", "S Grioni", "LC Groop", "R Kaaks", "TJ Key", "PM Nilsson", "K Overvad", "D Palli", "S Panico", "JR Quiros", "O Rolandsson", "C Sacerdote", "MJ Sanchez", "N Slimani", "B Teucher", "A Tjonneland", "R Tumino", "DL van der A", "EJM Feskens", "C Langenberg", "NG Forouhi", "E Riboli", "NJ Wareham", "I Consortium" ],
      "venue" : null,
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 2013
    }, {
      "title" : "Polycystic ovary syndrome is a risk factor for type 2 diabetes: Results from a long-term prospective study",
      "author" : [ "A Gambineri", "L Patton", "P Altieri", "U Pagotto", "C Pizzi", "L Manzoli", "R Pasquali" ],
      "venue" : "Diabetes",
      "citeRegEx" : "5",
      "shortCiteRegEx" : "5",
      "year" : 2012
    }, {
      "title" : "Gulanski BI: Association of endogenous sex hormones and insulin resistance among postmenopausal women: Results from the postmenopausal estrogen/progestin intervention trial",
      "author" : [ "GM Kalish", "E Barrett-Connor", "GA Laughlin" ],
      "venue" : "J Clin Endocr Metab",
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2003
    }, {
      "title" : "Testosterone, SHBG and cardiovascular health in postmenopausal women",
      "author" : [ "JS Brand", "YT van der Schouw" ],
      "venue" : "Int J Impot Res",
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2010
    }, {
      "title" : "Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies",
      "author" : [ "JS Brand", "I van der Tweel", "DE Grobbee", "MH Emmelot-Vonk", "YT van der Schouw" ],
      "venue" : "Int J Epidemiol",
      "citeRegEx" : "8",
      "shortCiteRegEx" : "8",
      "year" : 2011
    }, {
      "title" : "Endogenous sex hormones and glucose tolerance status in postmenopausal women",
      "author" : [ "SH Golden", "AS Dobs", "D Vaidya", "M Szklo", "S Gapstur", "P Kopp", "K Liu", "P Ouyang" ],
      "venue" : "J Clin Endocrinol Metab",
      "citeRegEx" : "9",
      "shortCiteRegEx" : "9",
      "year" : 2007
    }, {
      "title" : "Plasma sex steroid hormones and risk of developing type 2 diabetes in women: A prospective study",
      "author" : [ "EL Ding", "Y Song", "JE Manson", "N Rifai", "JE Buring", "S Liu" ],
      "venue" : "Diabetologia",
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2084
    }, {
      "title" : "Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo Study",
      "author" : [ "JY Oh", "E Barrett-Connor", "NM Wedick", "DL Wingard" ],
      "venue" : "Diabetes Care 2002;25:55-60",
      "citeRegEx" : "11",
      "shortCiteRegEx" : "11",
      "year" : 2002
    }, {
      "title" : "Golden SH: The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women",
      "author" : [ "RR Kalyani", "M Franco", "AS Dobs", "P Ouyang", "D Vaidya", "A Bertoni", "SM Gapstur" ],
      "venue" : "Journal of Clinical Endocrinology and Metabolism",
      "citeRegEx" : "12",
      "shortCiteRegEx" : "12",
      "year" : 2009
    }, {
      "title" : "The Rotterdam Study: 2014 objectives and design update",
      "author" : [ "A Hofman", "S Darwish Murad", "CM van Duijn", "OH Franco", "A Goedegebure", "MA Ikram", "CC Klaver", "TE Nijsten", "RP Peeters", "BH Stricker", "HW Tiemeier", "AG Uitterlinden", "MW Vernooij" ],
      "venue" : "Eur J Epidemiol",
      "citeRegEx" : "13",
      "shortCiteRegEx" : "13",
      "year" : 2013
    }, {
      "title" : "BHC: Methods of data collection and  Page 18 of 57  Diabetes  19 definitions of cardiac outcomes in the Rotterdam Study. European journal of epidemiology",
      "author" : [ "MJG Leening", "M Kavousi", "J Heeringa", "FJA van Rooij", "J Verkroost-van Heemst", "JW Deckers", "FUS Mattace-Raso", "G Ziere", "A Hofman", "Stricker" ],
      "venue" : null,
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2012
    }, {
      "title" : "Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement",
      "author" : [ "W Rosner", "RJ Auchus", "R Azziz", "PM Sluss", "H Raff" ],
      "venue" : "J Clin Endocrinol Metab",
      "citeRegEx" : "16",
      "shortCiteRegEx" : "16",
      "year" : 2007
    }, {
      "title" : "Golden SH: The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women",
      "author" : [ "RR Kalyani", "M Franco", "AS Dobs", "P Ouyang", "D Vaidya", "A Bertoni", "SM Gapstur" ],
      "venue" : "J Clin Endocrinol Metab",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 2009
    }, {
      "title" : "Multiple Imputation for Nonresponse in Surveys",
      "author" : [ "Rubin", "B. D" ],
      "venue" : "Investigative Radiology",
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 1987
    }, {
      "title" : "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement",
      "author" : [ "D Moher", "A Liberati", "J Tetzlaff", "DG Altman", "P Group" ],
      "venue" : "PLoS Med",
      "citeRegEx" : "19",
      "shortCiteRegEx" : "19",
      "year" : 2009
    }, {
      "title" : "Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group",
      "author" : [ "DF Stroup", "JA Berlin", "SC Morton", "I Olkin", "GD Williamson", "D Rennie", "D Moher", "BJ Becker", "TA Sipe", "SB Thacker" ],
      "venue" : "JAMA",
      "citeRegEx" : "20",
      "shortCiteRegEx" : "20",
      "year" : 2012
    }, {
      "title" : "Association of sex hormone-binding globulin and insulin resistance among Japanese-American subjects",
      "author" : [ "M Okubo", "M Tokui", "G Egusa", "M Yamakido" ],
      "venue" : "Diabetes Res Clin Pract",
      "citeRegEx" : "21",
      "shortCiteRegEx" : "21",
      "year" : 2000
    }, {
      "title" : "Diabetes Prevention Program.: Steroid Sex Hormones, Sex Hormone-Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program",
      "author" : [ "KC Mather KJ", "CA Christophi", "VR Aroda", "WC Knowler", "SE Edelstein", "JC Florez", "F Labrie", "SE Kahn", "RB Goldberg", "E Barrett-Connor" ],
      "venue" : "J Clin Endocrinol Metab",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2015
    }, {
      "title" : "Rexrode KM: Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women",
      "author" : [ "ME Weinberg", "JE Manson", "JE Buring", "NR Cook", "EW Seely", "PM Ridker" ],
      "venue" : "Metabolism",
      "citeRegEx" : "23",
      "shortCiteRegEx" : "23",
      "year" : 2006
    }, {
      "title" : "A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome",
      "author" : [ "JE Nestler", "LP Powers", "DW Matt", "KA Steingold", "SR Plymate", "RS Rittmaster", "JN Clore", "WG Blackard" ],
      "venue" : "J Clin Endocrinol Metab",
      "citeRegEx" : "24",
      "shortCiteRegEx" : "24",
      "year" : 1991
    }, {
      "title" : "Sex hormone-binding globulin and risk of type 2 diabetes in women and men",
      "author" : [ "EL Ding", "Y Song", "JE Manson", "DJ Hunter", "CC Lee", "N Rifai", "JE Buring", "JM Gaziano", "S Liu" ],
      "venue" : "N Engl J Med",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2009
    }, {
      "title" : "Sex hormone-binding globulin associations with circulating lipids and metabolites and the risk for type 2 diabetes: observational and causal effect estimates",
      "author" : [ "Q Wang", "AJ Kangas", "P Soininen", "M Tiainen", "T Tynkkynen", "K Puukka", "A Ruokonen", "J Viikari", "M Kahonen", "T Lehtimaki", "V Salomaa", "M Perola", "GD Smith", "OT Raitakari", "MR Jarvelin", "P Wurtz", "J Kettunen", "M Ala-Korpela" ],
      "venue" : "International Journal of Epidemiology",
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2015
    }, {
      "title" : "Study on the (TAAAA)n repeat polymorphism in sex hormone-binding globulin gene and the SHBG serum levels in putative association with the glucose metabolic status of Chinese patients suffering from polycystic ovarian syndrome in Shandong province",
      "author" : [ "JL Zhao", "ZJ Chen", "YR Zhao", "LX Zhao", "LC Wang", "Y Li", "R Tang", "YH Shi" ],
      "venue" : null,
      "citeRegEx" : "27",
      "shortCiteRegEx" : "27",
      "year" : 2005
    }, {
      "title" : "TM: Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes",
      "author" : [ "JR Perry", "MN Weedon", "C Langenberg", "AU Jackson", "V Lyssenko", "T Sparso", "G Thorleifsson", "H Grallert", "L Ferrucci", "M Maggio", "G Paolisso", "M Walker", "CN Palmer", "F Payne", "E Young", "Herder" ],
      "venue" : "Diabetes",
      "citeRegEx" : "28",
      "shortCiteRegEx" : "28",
      "year" : 2010
    }, {
      "title" : "NA: Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane",
      "author" : [ "W Rosner", "DJ Hryb", "MS Khan", "AM Nakhla", "Romas" ],
      "venue" : "J Steroid Biochem",
      "citeRegEx" : "29",
      "shortCiteRegEx" : "29",
      "year" : 1999
    }, {
      "title" : "Sex hormone-binding globulin antagonizes the anti-apoptotic effect of estradiol in breast cancer cells",
      "author" : [ "MG Catalano", "R Frairia", "G Boccuzzi", "N Fortunati" ],
      "venue" : "Mol Cell Endocrinol",
      "citeRegEx" : "30",
      "shortCiteRegEx" : "30",
      "year" : 2005
    }, {
      "title" : "Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer",
      "author" : [ "N Fortunati", "MG Catalano", "G Boccuzzi", "R Frairia" ],
      "venue" : "Mol Cell Endocrinol",
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 2010
    }, {
      "title" : "Heart, Estrogen/progestin Replacement S: Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, doubleblind, placebo-controlled trial",
      "author" : [ "AM Kanaya", "D Herrington", "E Vittinghoff", "F Lin", "D Grady", "V Bittner", "JA Cauley", "E BarrettConnor" ],
      "venue" : "Ann Intern Med",
      "citeRegEx" : "32",
      "shortCiteRegEx" : "32",
      "year" : 2003
    }, {
      "title" : "Women's Health Initiative I: Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial",
      "author" : [ "KL Margolis", "DE Bonds", "RJ Rodabough", "L Tinker", "LS Phillips", "C Allen", "T Bassford", "G Burke", "J Torrens", "BV Howard" ],
      "venue" : "Diabetologia",
      "citeRegEx" : "33",
      "shortCiteRegEx" : "33",
      "year" : 2004
    }, {
      "title" : "The effect of conjugated equine oestrogen on diabetes incidence: The Women's Health Initiative randomised trial",
      "author" : [ "DE Bonds", "N Lasser", "L Qi", "R Brzyski", "B Caan", "G Heiss", "MC Limacher", "JH Liu", "E Mason", "A Oberman", "MJ O'Sullivan", "LS Phillips", "RJ Prineas", "L Tinker" ],
      "venue" : "Diabetologia",
      "citeRegEx" : "34",
      "shortCiteRegEx" : "34",
      "year" : 2006
    }, {
      "title" : "TL: Effect of postmenopausal hormone therapy on glucose and insulin concentrations",
      "author" : [ "MA Espeland", "PE Hogan", "SE Fineberg", "G Howard", "H Schrott", "MA Waclawiw", "Bush" ],
      "venue" : "Diabetes Care 1998;21:1589-1595",
      "citeRegEx" : "35",
      "shortCiteRegEx" : "35",
      "year" : 1998
    }, {
      "title" : "The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in American Indian postmenopausal women - The Strong Heart Study",
      "author" : [ "Y Zhang", "CF Schaefer", "BV Howard", "RA Wild", "LD Cowan", "WY Wang", "JL Yeh", "ET Lee" ],
      "venue" : "Diabetes Care 2002;25:500-504",
      "citeRegEx" : "36",
      "shortCiteRegEx" : "36",
      "year" : 2002
    }, {
      "title" : "Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women",
      "author" : [ "TE Strandberg", "O Ylikorkala", "MJ Tikkanen" ],
      "venue" : "Am J Cardiol",
      "citeRegEx" : "37",
      "shortCiteRegEx" : "37",
      "year" : 2003
    }, {
      "title" : "Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women",
      "author" : [ "A Decensi", "U Omodei", "C Robertson", "B Bonanni", "A Guerrieri-Gonzaga", "F Ramazzotto", "H Johansson", "S Mora", "MT Sandri", "M Cazzaniga", "M Franchi", "S Pecorelli" ],
      "venue" : "Circulation",
      "citeRegEx" : "38",
      "shortCiteRegEx" : "38",
      "year" : 2002
    }, {
      "title" : "A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin",
      "author" : [ "SR Lindheim", "SC Presser", "EC Ditkoff", "MA Vijod", "FZ Stanczyk", "RA Lobo" ],
      "venue" : "Fertil Steril 1993;60:664-667",
      "citeRegEx" : "39",
      "shortCiteRegEx" : "39",
      "year" : 1993
    }, {
      "title" : "Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women",
      "author" : [ "D Goodman-Gruen", "E Barrett-Connor" ],
      "venue" : "Diabetes Care 2000;23:912-918",
      "citeRegEx" : "40",
      "shortCiteRegEx" : "40",
      "year" : 2000
    }, {
      "title" : "Postmenopausal Estrogen/Progestin Intervention T: Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial",
      "author" : [ "GM Kalish", "E Barrett-Connor", "GA Laughlin", "BI Gulanski" ],
      "venue" : "J Clin Endocrinol Metab",
      "citeRegEx" : "41",
      "shortCiteRegEx" : "41",
      "year" : 2003
    }, {
      "title" : "Menopause IMSW: Understanding weight gain at menopause",
      "author" : [ "SR Davis", "C Castelo-Branco", "P Chedraui", "MA Lumsden", "RE Nappi", "D Shah", "P Villaseca" ],
      "venue" : "Climacteric",
      "citeRegEx" : "42",
      "shortCiteRegEx" : "42",
      "year" : 2012
    }, {
      "title" : "A critical evaluation of simple methods for the estimation of free testosterone in serum",
      "author" : [ "A Vermeulen", "L Verdonck", "JM Kaufman" ],
      "venue" : "J Clin Endocr Metab",
      "citeRegEx" : "43",
      "shortCiteRegEx" : "43",
      "year" : 1999
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Menopause is an important transition in women’s life, not only for marking the end of reproductive life, but also for being accompanied by an increased risk of cardiovascular disease and type 2 diabetes (T2D) (1; 2).",
      "startOffset" : 209,
      "endOffset" : 215
    }, {
      "referenceID" : 1,
      "context" : "Menopause is an important transition in women’s life, not only for marking the end of reproductive life, but also for being accompanied by an increased risk of cardiovascular disease and type 2 diabetes (T2D) (1; 2).",
      "startOffset" : 209,
      "endOffset" : 215
    }, {
      "referenceID" : 2,
      "context" : "Changes in hormonal patterns in menopause, including the decline in endogenous estradiol levels and the relative androgen excess, contribute to an increase in visceral adiposity that is associated with glycemic traits, and therefore may influence the risk of T2D (3; 4).",
      "startOffset" : 263,
      "endOffset" : 269
    }, {
      "referenceID" : 3,
      "context" : "Changes in hormonal patterns in menopause, including the decline in endogenous estradiol levels and the relative androgen excess, contribute to an increase in visceral adiposity that is associated with glycemic traits, and therefore may influence the risk of T2D (3; 4).",
      "startOffset" : 263,
      "endOffset" : 269
    }, {
      "referenceID" : 5,
      "context" : "While the relation between sex-hormone binding globulin (SHBG) and T2D has long been recognized (6; 7), literature on the associations of steroid sex hormones such as endogenous estradiol (E) and testosterone (T) with T2D is scarce.",
      "startOffset" : 96,
      "endOffset" : 102
    }, {
      "referenceID" : 6,
      "context" : "While the relation between sex-hormone binding globulin (SHBG) and T2D has long been recognized (6; 7), literature on the associations of steroid sex hormones such as endogenous estradiol (E) and testosterone (T) with T2D is scarce.",
      "startOffset" : 96,
      "endOffset" : 102
    }, {
      "referenceID" : 5,
      "context" : "SHBG, T and E have been associated with glucose metabolism and development of insulin resistance (6-9).",
      "startOffset" : 97,
      "endOffset" : 102
    }, {
      "referenceID" : 6,
      "context" : "SHBG, T and E have been associated with glucose metabolism and development of insulin resistance (6-9).",
      "startOffset" : 97,
      "endOffset" : 102
    }, {
      "referenceID" : 7,
      "context" : "SHBG, T and E have been associated with glucose metabolism and development of insulin resistance (6-9).",
      "startOffset" : 97,
      "endOffset" : 102
    }, {
      "referenceID" : 8,
      "context" : "SHBG, T and E have been associated with glucose metabolism and development of insulin resistance (6-9).",
      "startOffset" : 97,
      "endOffset" : 102
    }, {
      "referenceID" : 12,
      "context" : "Details regarding the design, objectives, and methods of the Rotterdam Study have been described in detail elsewhere(13).",
      "startOffset" : 116,
      "endOffset" : 120
    }, {
      "referenceID" : 12,
      "context" : "Follow up examinations were performed periodically, approximately every 3-5 years(13).",
      "startOffset" : 81,
      "endOffset" : 85
    }, {
      "referenceID" : 13,
      "context" : "practitioners’ records, glucose hospital discharge letters and glucose measurements from Rotterdam Study visits which take place approximately every 4 years (14).",
      "startOffset" : 157,
      "endOffset" : 161
    }, {
      "referenceID" : 13,
      "context" : "Information regarding the use of blood glucose lowering medication was derived from both structured home interviews and linkage to pharmacy records (14).",
      "startOffset" : 148,
      "endOffset" : 152
    }, {
      "referenceID" : 14,
      "context" : "(T/SHBG)*100 is used as a surrogate measure of bioavailable testosterone (BT) (16).",
      "startOffset" : 78,
      "endOffset" : 82
    }, {
      "referenceID" : 9,
      "context" : "so only BMI was used as a measure of adiposity, consistent with previous studies (10; 17).",
      "startOffset" : 81,
      "endOffset" : 89
    }, {
      "referenceID" : 15,
      "context" : "so only BMI was used as a measure of adiposity, consistent with previous studies (10; 17).",
      "startOffset" : 81,
      "endOffset" : 89
    }, {
      "referenceID" : 16,
      "context" : "Rubin’s method was used for the pooled regression coefficients (β) and 95% Confidence Intervals (18).",
      "startOffset" : 96,
      "endOffset" : 100
    }, {
      "referenceID" : 17,
      "context" : "The review was conducted using a predefined protocol and in accordance with the PRISMA(19)",
      "startOffset" : 86,
      "endOffset" : 90
    }, {
      "referenceID" : 18,
      "context" : "and MOOSE(20) guidelines (S2 and S3 Appendix).",
      "startOffset" : 9,
      "endOffset" : 13
    }, {
      "referenceID" : 19,
      "context" : "5 nmol/l) during 3 years of followup but that was not significant different after adjusting for age, body mass index and waist to hip ratio(21).",
      "startOffset" : 139,
      "endOffset" : 143
    }, {
      "referenceID" : 20,
      "context" : "Sex steroids and SHBG were not associated with diabetes outcomes in pre and postmenopausal women in the study of Mather et al (22).",
      "startOffset" : 126,
      "endOffset" : 130
    }, {
      "referenceID" : 6,
      "context" : "SHBG levels have been associated with metabolic syndrome, glucose and insulin levels, established risk factors for T2D(7; 8; 23).",
      "startOffset" : 118,
      "endOffset" : 128
    }, {
      "referenceID" : 7,
      "context" : "SHBG levels have been associated with metabolic syndrome, glucose and insulin levels, established risk factors for T2D(7; 8; 23).",
      "startOffset" : 118,
      "endOffset" : 128
    }, {
      "referenceID" : 21,
      "context" : "SHBG levels have been associated with metabolic syndrome, glucose and insulin levels, established risk factors for T2D(7; 8; 23).",
      "startOffset" : 118,
      "endOffset" : 128
    }, {
      "referenceID" : 22,
      "context" : "Also, women with PCOS, a condition of anovulation and hyperandrogenism, are at increased risk of T2D, and levels of SHBG are decreased in these women (24).",
      "startOffset" : 150,
      "endOffset" : 154
    }, {
      "referenceID" : 23,
      "context" : "SHBG to associate with insulin resistance and T2D, suggesting that altered SHBG physiology may be a primarily defect in the pathogenesis of disease(25-28).",
      "startOffset" : 147,
      "endOffset" : 154
    }, {
      "referenceID" : 24,
      "context" : "SHBG to associate with insulin resistance and T2D, suggesting that altered SHBG physiology may be a primarily defect in the pathogenesis of disease(25-28).",
      "startOffset" : 147,
      "endOffset" : 154
    }, {
      "referenceID" : 25,
      "context" : "SHBG to associate with insulin resistance and T2D, suggesting that altered SHBG physiology may be a primarily defect in the pathogenesis of disease(25-28).",
      "startOffset" : 147,
      "endOffset" : 154
    }, {
      "referenceID" : 26,
      "context" : "SHBG to associate with insulin resistance and T2D, suggesting that altered SHBG physiology may be a primarily defect in the pathogenesis of disease(25-28).",
      "startOffset" : 147,
      "endOffset" : 154
    }, {
      "referenceID" : 27,
      "context" : "biologic action of sex hormones via activation of a specific plasma receptor(29-31).",
      "startOffset" : 76,
      "endOffset" : 83
    }, {
      "referenceID" : 28,
      "context" : "biologic action of sex hormones via activation of a specific plasma receptor(29-31).",
      "startOffset" : 76,
      "endOffset" : 83
    }, {
      "referenceID" : 29,
      "context" : "biologic action of sex hormones via activation of a specific plasma receptor(29-31).",
      "startOffset" : 76,
      "endOffset" : 83
    }, {
      "referenceID" : 27,
      "context" : "membrane high-affinity receptors (RSHBG)(29).",
      "startOffset" : 40,
      "endOffset" : 44
    }, {
      "referenceID" : 27,
      "context" : "For example, SHBG- RSHBG complex can have direct cellular antagonistic properties against estrogen; SHBG may interact with cellular estrogen receptors which can trigger a biologic antiestrogenic response(29).",
      "startOffset" : 203,
      "endOffset" : 207
    }, {
      "referenceID" : 30,
      "context" : "Our result for a positive relation between estradiol and T2D are in contrast with the results from previous large randomized control trials of oral estrogen therapy, which showed a lower risk of T2D among postmenopausal women assigned to estrogen treatment(32-34).",
      "startOffset" : 256,
      "endOffset" : 263
    }, {
      "referenceID" : 31,
      "context" : "Our result for a positive relation between estradiol and T2D are in contrast with the results from previous large randomized control trials of oral estrogen therapy, which showed a lower risk of T2D among postmenopausal women assigned to estrogen treatment(32-34).",
      "startOffset" : 256,
      "endOffset" : 263
    }, {
      "referenceID" : 32,
      "context" : "Our result for a positive relation between estradiol and T2D are in contrast with the results from previous large randomized control trials of oral estrogen therapy, which showed a lower risk of T2D among postmenopausal women assigned to estrogen treatment(32-34).",
      "startOffset" : 256,
      "endOffset" : 263
    }, {
      "referenceID" : 33,
      "context" : "Exogenous estrogen may have different physiological effects depending on type, route, duration and dose of estrogen therapy(35-38).",
      "startOffset" : 123,
      "endOffset" : 130
    }, {
      "referenceID" : 34,
      "context" : "Exogenous estrogen may have different physiological effects depending on type, route, duration and dose of estrogen therapy(35-38).",
      "startOffset" : 123,
      "endOffset" : 130
    }, {
      "referenceID" : 35,
      "context" : "Exogenous estrogen may have different physiological effects depending on type, route, duration and dose of estrogen therapy(35-38).",
      "startOffset" : 123,
      "endOffset" : 130
    }, {
      "referenceID" : 36,
      "context" : "Exogenous estrogen may have different physiological effects depending on type, route, duration and dose of estrogen therapy(35-38).",
      "startOffset" : 123,
      "endOffset" : 130
    }, {
      "referenceID" : 33,
      "context" : "For example, opposing effects of oral estrogen on fasting glucose vs glucose tolerance have been reported(35; 36).",
      "startOffset" : 105,
      "endOffset" : 113
    }, {
      "referenceID" : 34,
      "context" : "For example, opposing effects of oral estrogen on fasting glucose vs glucose tolerance have been reported(35; 36).",
      "startOffset" : 105,
      "endOffset" : 113
    }, {
      "referenceID" : 36,
      "context" : "treatment but not transdermal estradoil (38).",
      "startOffset" : 40,
      "endOffset" : 44
    }, {
      "referenceID" : 37,
      "context" : "insulin sensitivity whereas higher dose had the opposite effect(39).",
      "startOffset" : 63,
      "endOffset" : 67
    }, {
      "referenceID" : 40,
      "context" : "regulate body composition, may studies in postmenopausal women have failed to show a consistent beneficial role of estradiol in weight loss and in the distribution of body fat(42).",
      "startOffset" : 175,
      "endOffset" : 179
    }, {
      "referenceID" : 13,
      "context" : "These findings are in line with previous studies reporting higher levels of insulin resistance with increasing levels of BT in postmenopausal women, while no association has been observed between TT and insulin resistance(14; 41).",
      "startOffset" : 221,
      "endOffset" : 229
    }, {
      "referenceID" : 39,
      "context" : "These findings are in line with previous studies reporting higher levels of insulin resistance with increasing levels of BT in postmenopausal women, while no association has been observed between TT and insulin resistance(14; 41).",
      "startOffset" : 221,
      "endOffset" : 229
    }, {
      "referenceID" : 13,
      "context" : "Similarly, BT has been related to increased odds of having impaired fasting glucose(14).",
      "startOffset" : 83,
      "endOffset" : 87
    }, {
      "referenceID" : 41,
      "context" : "Nevertheless, free T levels in this study were derived from the ratio of T to SHBG, which is considered a precise proxy for bioavailable T(43).",
      "startOffset" : 138,
      "endOffset" : 142
    } ],
    "year" : 2016,
    "abstractText" : "It remains unclear whether endogenous sex hormones (ESH) are associated with risk of type 2 diabetes (T2D) in women. Data of 3117 postmenopausal women participants of the Rotterdam Study (RS) were analysed to examine whether ESH and sex hormone-binding globulin (SHBG) were associated with the risk of incident T2D. Additionally, we performed a systematic review and meta-analysis of studies assessing the prospective association of ESH and SHBG with T2D in women. During a median follow-up of 11.1 years, we identified 384 incident cases of T2D in the RS. No association was observed between total (TT) or bioavailable testosterone (BT) with T2D. SHBG was inversely associated with the risk of T2D whereas total estradiol (TE) was associated with increased risk of T2D. Similarly, in the meta-analysis of 13 population-based prospective studies involving more than 1912 incident T2D cases, low levels of SHBG and high levels of TE were associated with increased risk of T2D, while no associations were found for other hormones. The association of SHBG with T2D did not change by menopause status, while the associations of ESH and T2D were based only in postmenopausal women. SHBG and TE are independent risk factors for the development of T2D in women. Page 2 of 57 Diabetes",
    "creator" : "SPDF"
  }
}